Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 68 clinical trials
Featured trial

The purpose of this study is to see if Lenacapavir is safe and effective to use as PrEP in Cisgender Men (CGM), Transgender Women (TGW), Transgender Men (TGM) and Gender Non-binary people (GNB), with a high risk of HIV infection. This study will also assess how effective LEN is when …

  • 25 Aug, 2023
  • 1 location
Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection

Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

  • 25 Apr, 2022
  • 1 location
  • 05 Sep, 2023
  • 1 location
Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda (PeerPREP)

Purpose: The purpose of the project is to determine oral pre-exposure prophylaxis (PrEP) preference among 14-24-year-old adolescent girls and young women (AGYW) at risk of HIV infection and to evaluate a peer support intervention aimed at improving uptake of and adherence to oral PrEP. Main Study Aims: i) To determine …

Accepts healthy volunteers
  • 11 Apr, 2023
  • 1 location
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

The study is being conducted to determine if cenicriviroc mesylate (CVC) will decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta.

  • 13 Sep, 2023
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

The ANRS 171 SYNACTHIV trial is an international multicenter pilot open label phase I trial. This trial will evaluate new procedures in LRA administration in 3 successive cohorts. In case of grade 3 to grade 5 adverse events, the inclusions and treatments will be (but not in a definitive manner) …

  • 11 Sep, 2023
  • 1 location
Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients

Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with

  • 16 Feb, 2022
  • 1 location
Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and swallowability of formulation among the pediatric population. The dose selection of FTR for children and adolescents ≥20kg utilized …

  • 06 Apr, 2023
  • 4 locations
Open-label, Follow-up of Doravirine/Islatravir for Participants With Human Immunodeficiency Virus -1 (HIV-1) Infection (MK-8591A-033)

The safety and tolerability of MK-8591A, a novel 2-drug fixed dose combination (FDC) of doravirine (DOR) and islatravir (ISL) will be evaluated in adult and pediatric participants with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clinical studies.

  • 20 Sep, 2023
  • 20 locations
A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

(formerly GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN

  • 18 Sep, 2023
  • 25 locations